LATEST PRESS RELEASES

FEBRUARY 22, 2024 / REGULATORY

IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam

Gothenburg, Sweden, 22 February 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s recent End-of-Phase 2 meeting with the US Food and Drug administration, FDA, was held in a constructive and engaging spirit. The discussions during the meeting indicate alignment between the FDA and IRLAB on the design of the Phase III program.

Read More >
FEBRUARY 7, 2024 / REGULATORY

IRLAB publishes year-end report for the period January-December 2023

Read More >
FEBRUARY 6, 2024

IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines

Read More >
EVENT CALENDAR

FINANCIAL CALENDAR

NEXT

week 18 (April 29-May 3)

Annual report

FOLLOWING

May 8, 2024

Interim report January-March 2024